New COPD drug Hemay005 enters Mid-Stage trial

NCT ID NCT07314242

Not yet recruiting Disease control Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2a trial tests whether Hemay005 can reduce lung inflammation in people with moderate to severe COPD. About 120 adults will take Hemay005, the existing drug roflumilast, or a placebo for 12 weeks. Researchers will measure changes in sputum and blood markers to see if Hemay005 is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hemay005
What this could lead to: If it works, this could point toward a new treatment option for COPD that reduces lung inflammation and improves breathing.
What could go wrong: This is an early Phase 2a study with only 120 participants, so results may not apply to everyone. The drug may not work better than existing treatments or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)

Contacts and locations

Locations

China People's Armed Police Force Characteristic Medical Center

Tianjin, 300162, China
Tianjin Fourth Central Hospital

Tianjin, 300074, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.